Decision analysis in nuclear medicine

Journal of Nuclear Medicine

Volumn 40, Issue 9, 1999, Pages 1570-1581

  Gambhir, Sanjiv Sam ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Decision modeling; Meta analysis

Indexed keywords

ARTICLE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DECISION THEORY; ECONOMIC ASPECT; LIFE EXPECTANCY; META ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; TECHNOLOGY;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; HUMANS; LIFE EXPECTANCY; META-ANALYSIS; NUCLEAR MEDICINE; QUALITY OF LIFE;

EID: 0032821966     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. McCombs JS. Pharmacoeconomics: what is it and where is it going? Am J Hypertens. 1998;11(suppl):112S-119S.
2. Till M. Payer evaluates medical procedures. In: Mission KS, ed. IMDA Update. New York, NY: Independent Medical Distributors Association; 1997;14-22.
3. Smith ML, Glass GV. Meta-analysis of psychotherapy outcome studies. Am Psychol. 1977;32:752-760.
4. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Wed. 1987;107:224-233.
5. Thacker SB. Meta-analysis. A quantitative approach to research integration. JAMA. 1988;259:1685-1689.
6. Irwig L, Macaskill P, Glasziou P, Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol. 1995;48:119-132.
7. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983;39:207-215.
8. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293-1316.
9. Albert A. On the use and computation of likelihood ratios in clinical chemistry. Clin Chem. 1982;28:1113-1119.
10. Irwig L. Modelling result-specific likelihood ratios [letter; comment], J Clin Epidemiol. 1992;45:1335-1338.
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
12. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1-31.
13. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med. 1996;37:1428-1436.
14. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg. 1998;66:1876-1883.
15. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-1341.
16. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost Effectiveness in Health and Medicine. Pharmacogenetics. 1997;11:159-168.
17. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost Effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
18. Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care. 1990;6:93-103.
19. Stalpers LJ, Van Gasteren HJ, Van Daal WA. DEALE-ing with life expectancy and mortality rates. Med Decis Making. 1989;9:150-152. See also erratum in Med Decis Making. 1989;9:219.
20. Froberg DG, Kane RL. Methodology for measuring health-state preferences. III: Population and context effects. J Clin Epidemiol. 1989;42:585-592.
21. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988;23:203-235.
22. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16: 2113-2125.
23. Gambhir SS, Gupta P, Shepherd JE, et al. MD@: a physician-friendly decision analysis tool. MD Comput. 1998;15:40-48.
24. Bhargava HK, Sridhar S, Herrick C. Beyond spreadsheets: tools for building decision support systems. Computer. 1999;32:31-39.
25. Garter AM, Phelps CE. Economic foundations of cost-effectiveness analysis: working papers series. Nat Bur Econ Res. 1992;4164:1-34.
26. Littenberg B, Mushlin AI. Technetium bone scanning in the diagnosis of osteomyelitis: a meta-analysis of test performance. Diagnostic Technology Assessment Consortium. J Gen Intern Med. 1992;7:158-154.
27. Devous MD Sr, Thisted RA, Morgan GF, Leroy RF, Rowe CC. SPECT brain imaging in epilepsy: a meta-analysis. J Nucl Med. 1998;39:285-293.
28. Lamelle M. Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q J Nucl Med. 1998;42:211-221.
29. Hillner BE. Decision analysis: MIBI imaging of nonpalpable breast abnormalities. J Nucl Med. 1997;38:1772-1778.
30. Waxman AD. A perspective on decision analysis modeling as it relates to sestamibi imaging of nonpalpable breast abnormalities [editorial, comment]. J Nucl Med. 1997;38:1778-1780.
31. Patterson RE, Eng C, Horowitz SF, Gorlin R, Goldstein SR. Bayesian comparison of cost-effectiveness of different clinical approaches to diagnose coronary artery disease. J Am Col Cardiol. 1984;4:278-289.
32. Patterson RE. Cost-effectiveness analysis in diagnosis of cardiac disease: overview of its rationale and method. J Nucl Cardiol. 1996;3:334-341.
33. Allen M, Hendi P, Bassett L, Phelps ME, Gambhir SS. A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breasts for breast cancer. Breast Cancer Res Treat. 1999:in press.